Phase II Study of Docetaxel and Gefitinib as Second-Line Therapy in Gemcitabine Pretreated Patients with Advanced Pancreatic Cancer

Publisher： Karger

E-ISSN： 1423-0232|76|4|270-274

ISSN： 0030-2414

Source： Oncology, Vol.76, Iss.4, 2009-03, pp. : 270-274

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Multicenter Phase II Study of Docetaxel in Combination with Gefitinib in Gemcitabine-Pretreated Patients with Advanced/Metastatic Pancreatic Cancer

By  

Oncology, Vol. 71, Iss. 3-4, 2007-07 ,pp. : 159-163

Karger

Access to resources Recommend Favorite

Gefitinib in Combination with Capecitabine as Second-Line Therapy in Patients with Advanced Colorectal Cancer (aCRC): A Phase I/II Study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

By  

Oncology Research and Treatment, Vol. 33, Iss. 3, 2010-02 ,pp. : 89-93

Karger

Access to resources Recommend Favorite

Weekly Docetaxel with or without Gemcitabine as Second-Line Chemotherapy in Paclitaxel-Pretreated Patients with Metastatic Breast Cancer: A Randomized Phase II Study Conducted by the Hellenic Co-Operative Oncology Group

By  

Oncology, Vol. 77, Iss. 3-4, 2009-09 ,pp. : 212-216

Karger

Access to resources Recommend Favorite

Multicenter Phase II Study of Gemcitabine and Oxaliplatin (GEMOX) as Second-Line Chemotherapy in Colorectal Cancer Patients Pretreated with 5-Fluorouracil plus Irinotecan

By  

Oncology, Vol. 70, Iss. 2, 2006-05 ,pp. : 106-114

Karger

Access to resources Recommend Favorite

Second-Line Therapy in Refractory Pancreatic Cancer. Results of a Phase II Study

By  

Oncology Research and Treatment, Vol. 32, Iss. 3, 2009-02 ,pp. : 99-102

Karger

Access to resources Recommend Favorite